Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12480676.
- Also identified by PMC identifier 1754306.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The seronegative spondyloarthropathies (SpAs) are associated both with clinical and subclinical colitis. Recently biological blockade with the tumour necrosis factor alpha (TNFalpha) antagonists infliximab and etanercept has been shown to be effective in the treatment of SpA. However, only infliximab is efficacious in the treatment of colitis in patients with Crohn's SpA. We report on two patients with SpA and associated Crohn's disease treated with etanercept whose arthritis showed an excellent response with complete resolution of spinal pathology, whereas their Crohn's disease persisted or flared. These findings suggest that the effect of TNFalpha blockade in SpA differs between the joint and the bowel.
Medical subject headings
- Crohn Disease
- Immunoglobulin G
- Immunosuppressive Agents
- Receptors, Tumor Necrosis Factor
- Spondylarthritis